Sermorelin

Research-Grade

Sermorelin is the synthetic form of the first 29 amino acids of human growth-hormone-releasing hormone (GHRH 1-29 NH₂) — the minimum sequence required for full biological activity on the GHRH receptor. Developed in the 1970s–80s and subsequently marketed as Geref (now discontinued), it was historically used as a diagnostic tool to assess pituitary GH reserve and therapeutically for pediatric GH deficiency before losing favor to recombinant human GH. Sermorelin remains in widespread use in US anti-aging and hormone-optimization clinics, often as a compounded subcutaneous injection. Compared to newer GHRH analogs: it has a short biological half-life (roughly 10–15 minutes), which produces a discrete GH pulse aligned with endogenous physiology but requires frequent dosing. CJC-1295 (no-DAC) and Modified GRF 1-29 are chemically related; tesamorelin is the FDA-approved long-acting successor. Clinical evidence is broader for diagnostic use than for outcome-driven chronic therapy. The enthusiasm among practitioners is partly physiological (preserved negative feedback, reduced downregulation vs rhGH) and partly economic (compounded Sermorelin is substantially cheaper than rhGH therapy).